Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpACIN-neo: Neoadjuvant Ipilimumab + Nivolumab in Stage III Melanoma
NCT02977052Phase 2Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2016
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of ipilimumab and nivolumab in melanoma (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Frequency of grade 3/4 immune-related adverse events at 12 weeks, Objective Response Rate at 6 weeks and 1 more. Status: unknown.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02977052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977052.